These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20889761)

  • 1. Too much of a good thing is bad: proteasome inhibition induces stressed hearts to fail.
    Carrier L
    Cardiovasc Res; 2010 Dec; 88(3):389-90. PubMed ID: 20889761
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.
    Tang M; Li J; Huang W; Su H; Liang Q; Tian Z; Horak KM; Molkentin JD; Wang X
    Cardiovasc Res; 2010 Dec; 88(3):424-33. PubMed ID: 20601385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 5. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M; Lauer C; Beck U; Groettrup M
    J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.
    Cvek B
    Hum Reprod; 2009 Nov; 24(11):2967; author reply 2967-8. PubMed ID: 19687055
    [No Abstract]   [Full Text] [Related]  

  • 8. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA; Chacko A; Mutti L
    Oncogene; 2008 Feb; 27(9):1189-97. PubMed ID: 17828309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer research. Taking garbage in, tossing cancer out?
    Garber K
    Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteasome inhibitors as therapeutics.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Essays Biochem; 2005; 41():205-18. PubMed ID: 16250907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Van Herck JL; De Meyer GR; Martinet W; Bult H; Vrints CJ; Herman AG
    Basic Res Cardiol; 2010 Jan; 105(1):39-50. PubMed ID: 19693627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
    Tsukamoto S; Yokosawa H
    Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
    Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
    Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors: poisons and remedies.
    Meiners S; Ludwig A; Stangl V; Stangl K
    Med Res Rev; 2008 Mar; 28(2):309-27. PubMed ID: 17880010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
    Fuchs SY
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):9-10. PubMed ID: 18353138
    [No Abstract]   [Full Text] [Related]  

  • 18. "Change can happen" by PKA: proteasomes in in vivo hearts.
    Akazawa H; Komuro I
    J Mol Cell Cardiol; 2009 Apr; 46(4):445-7. PubMed ID: 19162036
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.